<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92320">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790854</url>
  </required_header>
  <id_info>
    <org_study_id>BLESS Study</org_study_id>
    <nct_id>NCT01790854</nct_id>
  </id_info>
  <brief_title>BLeeding Events and Maintenance DoSe of PraSugrel</brief_title>
  <acronym>BLESS</acronym>
  <official_title>Bless Study (BLeeding Events and Maintenance DoSe of PraSugrel)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Antoniucci</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ARCARD ONLUS Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Careggi Hospital</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim:  to verify if after the acute phase of ACS acute coronary syndrome (1-months), from 1
      to 12 months the reduction of maintenance dose of prasugrel from 10 mg to 5 mg/day may
      reduce the bleeding events (5 mg vs 10 mg). All patients will be treated with 325 mg of
      aspirin followed by a maintenance dosage of  100 mg of aspirin for at least 1 year. At
      baseline (after 60 mg loading dose of prasugrel) and after 1 month (7 days after the
      randomization at 10 or 5 mg of prasugrel) all patients will undergo light transmittance
      aggregometry (LTA) test to evaluate residual platelet reactivity (pharmacodynamic effects).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>bleeding</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>major, minor and minimal bleeding defined according BARC (Bleeding Academic Research Consurtium criteria (11), occurring from 1 month to the end of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>MACE (cardiac death, Myocardial Infarction, stroke) occurring from 1 month to the end of the study; late stent thrombosis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>pharmacodynamic effects</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>pharmacodynamic effects of shifting prasugrel maintenance dose from 10 mg to 5 mg after ACS</description>
  </other_outcome>
  <other_outcome>
    <measure>residual platelet reactivity (LTA)</measure>
    <time_frame>baseline - 1 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>correlation between residual platelet reactivity (LTA), both at baseline and at 1-month, with bleeding and ischemic events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Adverse Reaction to Antiplatelet Agent</condition>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel dose 5 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of  100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 5 mg/day of prasugrel for 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel dose 10 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>225 patients will be treated with 325 mg of aspirin (followed by a maintenance dosage of  100 mg of aspirin for at least 1 year and with 60 mg loading dose of prasugrel followed by a maintenance dosage of 10 mg/day of prasugrel for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel dose 5 mg/day</intervention_name>
    <arm_group_label>Prasugrel dose 5 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel dose 10 mg/day</intervention_name>
    <arm_group_label>Prasugrel dose 10 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all ACS patients treated with PCI (percutaneous coronary intervention) and dual
             antiplatelet therapy (DAPT: aspirin plus prasugrel).

          -  Informed written consent

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  Active bleeding; bleeding diathesis; coagulopathy

          -  History of gastrointestinal or genitourinary bleeding &lt;2 months

          -  Major surgery in the last 6 weeks

          -  History of intracranial bleeding or structural abnormalities

          -  Suspected aortic dissection

          -  Any previous TIA (transient ischemic attack)/stroke

          -  Administration in the week before the index event of clopidogrel, ticlopidine,
             prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or
             fondaparinux .

          -  Known relevant hematological deviations: Hb &lt;10 g/dl, Thrombocytopenia. &lt;100x10^9/l

          -  Use of coumadin derivatives within the last 7 days

          -  Chronic therapy with prasugrel or ticagrelor

          -  Known malignancies or other comorbid conditions with life expectancy &lt;1 year

          -  Known severe liver disease, severe renal failure

          -  Known allergy to the study medications

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Antoniucci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Careggi Hospital, division of Invasive Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Antoniucci, MD</last_name>
    <phone>+390557947966</phone>
    <email>david.antoniucci@virgilio.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nazario Carrabba, MD</last_name>
    <phone>+390557947966</phone>
    <email>n.carrabba@virgilio.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Careggi Hospital</name>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Antoniucci, MD</last_name>
      <phone>+390557947966</phone>
      <email>david.antoniucci@virgilio.it</email>
    </contact>
    <contact_backup>
      <last_name>Nazario Carrabba, MD</last_name>
      <phone>+390557947966</phone>
      <email>n.carrabba@virgilio.it</email>
    </contact_backup>
    <investigator>
      <last_name>David Antoniucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 12, 2013</lastchanged_date>
  <firstreceived_date>February 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Careggi Hospital</investigator_affiliation>
    <investigator_full_name>David Antoniucci</investigator_full_name>
    <investigator_title>Head Division of Invasive Cardiology</investigator_title>
  </responsible_party>
  <keyword>prasugrel</keyword>
  <keyword>antiplatelet</keyword>
  <keyword>Acute Coronary Syndrome</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prasugrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
